Archive
-
Working Paper
Working Paper SeriesMasters of Illusion: Bank and Regulatory Accounting for Losses in Distressed Banks
Sep 2020
The study seeks to explain why the instruments of central banking inevitably break down over time.
-
Working Paper
Working Paper SeriesGovernment as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019
Sep 2020
Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019
-
Working Paper
Working PaperHow “Maximizing Shareholder Value” Minimized the Strategic National Stockpile: The $5.3 Trillion Question for Pandemic Preparedness Raised by the Ventilator Fiasco
Jul 2020
The success of projects for pandemic preparedness and response depends on the strength of government-business collaborations.
-
Working Paper
Working Paper SeriesEmployment and Earnings of African Americans Fifty Years After: Progress?
Jul 2020
To fulfill MLK’s vision of jobs and freedom for Black Americans, Washington must rein in corporate greed
-
Working Paper
Working Paper SeriesHow the Disappearance of Unionized Jobs Obliterated an Emergent Black Middle Class
Jun 2020
In this introduction to our project, “Fifty Years After: Black Employment in the United States Under the Equal Employment Opportunity Commission,” we outline the socioeconomic forces behind the promising rise and disastrous fall of an African American blue-collar middle class.
-
Working Paper
Working Paper SeriesProfits, Innovation and Financialization in the Insulin Industry
Apr 2020
This paper considers the relationship between profits realized from higher insulin list prices, pharmaceutical innovation, and the financial structures of the three dominant insulin manufacturing companies, which set list prices.
-
Working Paper
Working Paper SeriesHow Much Can the U.S. Congress Resist Political Money? A Quantitative Assessment
Apr 2020
The links between campaign contributions from the financial sector and switches to a pro-bank vote were direct and substantial
-
Working Paper
Working Paper SeriesPrivate Equity Buyouts in Healthcare: Who Wins, Who Loses?
Mar 2020
Private equity firms have become major players in the healthcare industry. How has this happened and what are the results?
-
Working Paper
Working Paper SeriesThe Global Impact of Brexit Uncertainty
Dec 2019
Using tools from computational linguistics, we construct new measures of the impact of Brexit on listed firms in the United States and around the world
-
Working Paper
Working Paper SeriesFirm-Level Political Risk: Measurement and Effects
Jul 2019
We adapt simple tools from computational linguistics to construct a new measure of political risk faced by individual US firms: the share of their quarterly earnings conference calls that they devote to political risks.
-
Working Paper
Working Paper SeriesUS Pharma’s Financialized Business Model
Jul 2017
Price gouging in the US pharmaceutical drug industry goes back more than three decades.
-
Working Paper
Working Paper SeriesThe Functions of the Stock Market and the Fallacies of Shareholder Value
Jun 2017
Conventional wisdom has it that the primary function of the stock market is to raise cash for companies for the purpose of investing in productive capabilities. The conventional wisdom is wrong.
-
Working Paper
Working Paper SeriesThe Mismeasure of Mammon: Uses and Abuses of Executive Pay Data
Aug 2016
Report to the Institute for New Economic Thinking on the statistical measurement and policy implications of the compensation of the highest- paid U.S. corporate executives
-
Working Paper
Working Paper SeriesPolitical Lending
Aug 2016
Using a unique dataset provided by the Center for Responsive Politics (CRP), we document a direct channel through which financial institutions contribute to the net worth of members of the U.S. Congress, particularly those sitting on the finance committees in the Senate and the House of Representatives.
-
Working Paper
Working Paper SeriesEthics vs. Ethos in US and UK Megabanking
May 2016
Company law in the US and UK fails to acknowledge that authorities’ propensity to rescue giant banks from the consequences of insolvency assigns taxpayers a coerced and badly structured equity stake in too-big-to-fail institutions.